Latest news with #WuXiAppTec
The Standard
3 days ago
- Business
- The Standard
China pharma projects disrupted by Sino-US tensions
The logo of Chinese drug research and development group WuXi AppTec February 5, 2024. REUTERS
New Straits Times
3 days ago
- Business
- New Straits Times
China pharma projects disrupted by Sino-US tensions
SHANGHAI: Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of the matter, as they seek to mitigate the impact of US-China trade tensions. China's sprawling pharmaceutical research and manufacturing sector serves global drug giants such as Pfizer and AstraZeneca with a low-cost development model that often uses imported clinical samples, equipment, chemicals and other materials to conduct work. Fears of delay in access to US supply chains and raised import tariffs are spurring biotech and pharmaceutical companies to avoid, pause or consider delaying the start of projects, according to three sources. They are also discussing testing US clinical samples in the US, instead of sending them to China for further research, a move that could increase costs, and requesting additional supplies for backup, three other sources said. The six sources who spoke to Reuters are director or executive-level employees involved in various aspects of the industry in China including research and development, manufacturing and supply chains. All but two agreed to speak only on condition of anonymity because of concerns about effects on fundraising plans or they were not authorised to speak to media. The developments have not been reported previously. US and Chinese officials said last week they had agreed on a framework to put a May trade truce back on track and remove China's export restrictions on rare earths, but offered little sign of a durable resolution to longstanding trade differences that have affected products ranging from semiconductors and jet engines to medical equipment and pharmaceuticals. "What kind of long-term policy it could be, you know, what kind of tariff would it be in half a year, in one year... nobody knows. And that's the problem. That's what makes everybody worry and nervous," said Chen Gong, co-founder of NeuExcell Therapeutics, a biotech with its main operations in Suzhou. He said the US-China trade tensions had made him more cautious about investing in a clinical trial and the company would delay its start if it did not have sufficient funding. Reliance on US imports has come into particular focus as trade tensions escalate. In 2024, the US exported diagnostic and laboratory reagents to China valued at about US$1.4 billion and prepared culture media for the development or maintenance of microorganisms worth about US$125 million, U.N. Comtrade data showed. In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare industry, some US-made goods including diagnostic reagents from Germany's Siemens Healthineers were exempted from raised Chinese tariffs, that company said in May. China raised its tariffs on US imports to as much as 125 per cent though it has since reduced that to 10 per cent while it works out a more permanent trade deal. HIGHER COSTS, DELAYS WuXi AppTec and a Chinese biotechnology firm that was its research client agreed in May to switch US-made reagents they had been using for a Hepatitis B virus pre-clinical research project into non-U.S. versions due partly to concerns about higher costs from tariffs, a source at the client company said. The project had been temporarily paused during the discussions, which began prior to May, the source said. WuXi AppTec said it makes "every effort to avoid disruptions or delays in the delivery of services to customers." Since April, at least 17 Chinese biotech and pharmaceutical clients have contacted Chinese cell culture media manufacturer JS Biosciences asking it to keep locally-made backup raw materials for production because they were concerned about cost increases or the inability to access foreign supplies, the firm's CEO Luo Shun said. "If they have a product made by us, and we rely on the foreign raw material supply and that raw material will increase in price or is never going to come, obviously it will impact their manufacturing of those life-saving drugs. So obviously, that's their primary concern," Luo said. Another Chinese drug research and development firm decided not to provide a quotation to a foreign pharmaceutical company interested in hiring it for protein drug manufacturing, due to delays in obtaining necessary US-made culture medium from a US subsidiary of Japan's Fujifilm, a source at the Chinese firm said. The potential client would likely not have accepted waiting on imports of new supplies into China, which would typically take two to four months, the source said. A Fujifilm Holdings America Corporation spokesperson said Fujifilm Biosciences, one of its life science business units, has made significant investments to build a robust global manufacturing network so that it could navigate any challenges or disruptions, without elaborating on its supply issue involving China. STOCKPILING, US TESTING After China announced a large rise in tariffs for US imports in April, WuXi Biologics placed a bigger-than-normal order for reagents made in the US with a supplier because it was not sure how long that policy action would continue, said a source at the supplier. WuXi Biologics did not respond to requests for comment. Concerns about the potential for US export restrictions led China's Innovent Biologics and multinational BeOne Medicines to discuss with Massachusetts-headquartered Thermo Fisher Scientific the prospect of not sending US clinical samples to China, said a source at the US company. Testing US samples in-country instead of in China would be more expensive, the source said.
Yahoo
3 days ago
- Business
- Yahoo
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near-term science-based emissions reduction targets. The validation of these targets affirms that the Company's planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature rise to 1.5°C, underscoring WuXi AppTec's commitment to meaningful action for a more sustainable future. With the SBTi validation, WuXi AppTec commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, based on 2024 levels. The Company also aims to reduce absolute Scope 3 GHG emissions from purchased goods and services and fuel- and energy-related activities by 25% within the same timeframe (Scopes 1, 2, 3 are internationally recognized ways of classifying greenhouse gas emissions). The SBTi enables companies and financial institutions worldwide to play a pivotal role in combating the climate crisis. It develops standards, tools, and guidance that enable organizations to set GHG emissions reduction targets in line with what is required to keep global heating below catastrophic levels and achieve net-zero by 2050. "SBTi validation of WuXi AppTec's near-term targets marks an important milestone in our Company's sustainability journey," said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec's ESG Committee. "This recognition underscores our commitment to corporate social responsibility, scientific rigor, and transparency of our greenhouse gas emission reduction efforts. WuXi AppTec is dedicated to supporting our customers in delivering innovative therapies to patients worldwide, working together toward a healthier and more sustainable future." To achieve these targets, WuXi AppTec is implementing measures such as process optimization, equipment upgrades, infrastructure renovation, and technological innovations to enhance energy efficiency. The Company is also increasing its use of renewable energy by purchasing green electricity and installing photovoltaic power generation facilities. These efforts aim to progressively reduce carbon emissions within operational boundaries. Furthermore, WuXi AppTec is collaborating with suppliers to reduce absolute GHG emissions associated with purchased goods and services, fostering progress toward a low-carbon supply chain. As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec strategically integrates sustainability priorities like most of the customers into its global business operations. The Company has received an AA rating in the MSCI ESG ratings for four consecutive years, inclusion in the Dow Jones Sustainability Index (DJSI) for the same duration, and an A- Leadership rating in the CDP Climate Change rating for three consecutive years. WuXi AppTec has also been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics and received an A Leadership rating in the CDP Water Security rating, as well as a Gold Medal in the EcoVadis sustainability rating. To further its commitment to sustainability, WuXi AppTec has joined the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI) as a supplier partner. About WuXi AppTec As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." View original content: SOURCE WuXi AppTec Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
3 days ago
- Business
- Associated Press
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near-term science-based emissions reduction targets. The validation of these targets affirms that the Company's planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature rise to 1.5°C, underscoring WuXi AppTec's commitment to meaningful action for a more sustainable future. With the SBTi validation, WuXi AppTec commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, based on 2024 levels. The Company also aims to reduce absolute Scope 3 GHG emissions from purchased goods and services and fuel- and energy-related activities by 25% within the same timeframe (Scopes 1, 2, 3 are internationally recognized ways of classifying greenhouse gas emissions). The SBTi enables companies and financial institutions worldwide to play a pivotal role in combating the climate crisis. It develops standards, tools, and guidance that enable organizations to set GHG emissions reduction targets in line with what is required to keep global heating below catastrophic levels and achieve net-zero by 2050. 'SBTi validation of WuXi AppTec's near-term targets marks an important milestone in our Company's sustainability journey,' said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec's ESG Committee. 'This recognition underscores our commitment to corporate social responsibility, scientific rigor, and transparency of our greenhouse gas emission reduction efforts. WuXi AppTec is dedicated to supporting our customers in delivering innovative therapies to patients worldwide, working together toward a healthier and more sustainable future.' To achieve these targets, WuXi AppTec is implementing measures such as process optimization, equipment upgrades, infrastructure renovation, and technological innovations to enhance energy efficiency. The Company is also increasing its use of renewable energy by purchasing green electricity and installing photovoltaic power generation facilities. These efforts aim to progressively reduce carbon emissions within operational boundaries. Furthermore, WuXi AppTec is collaborating with suppliers to reduce absolute GHG emissions associated with purchased goods and services, fostering progress toward a low-carbon supply chain. As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec strategically integrates sustainability priorities like most of the customers into its global business operations. The Company has received an AA rating in the MSCI ESG ratings for four consecutive years, inclusion in the Dow Jones Sustainability Index (DJSI) for the same duration, and an A- Leadership rating in the CDP Climate Change rating for three consecutive years. WuXi AppTec has also been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics and received an A Leadership rating in the CDP Water Security rating, as well as a Gold Medal in the EcoVadis sustainability rating. To further its commitment to sustainability, WuXi AppTec has joined the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI) as a supplier partner. About WuXi AppTec As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that 'every drug can be made and every disease can be treated.' View original content: SOURCE WuXi AppTec
Yahoo
4 days ago
- Business
- Yahoo
China pharma projects disrupted by Sino-US tensions
By Andrew Silver SHANGHAI (Reuters) -Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of the matter, as they seek to mitigate the impact of U.S.-China trade tensions. China's sprawling pharmaceutical research and manufacturing sector serves global drug giants such as Pfizer and AstraZeneca with a low-cost development model that often uses imported clinical samples, equipment, chemicals and other materials to conduct work. Fears of delay in access to U.S. supply chains and raised import tariffs are spurring biotech and pharmaceutical companies to avoid, pause or consider delaying the start of projects, according to three sources. They are also discussing testing U.S. clinical samples in the U.S., instead of sending them to China for further research, a move that could increase costs, and requesting additional supplies for backup, three other sources said. The six sources who spoke to Reuters are director or executive-level employees involved in various aspects of the industry in China including research and development, manufacturing and supply chains. All but two agreed to speak only on condition of anonymity because of concerns about effects on fundraising plans or they were not authorised to speak to media. The developments have not been reported previously. U.S. and Chinese officials said last week they had agreed on a framework to put a May trade truce back on track and remove China's export restrictions on rare earths, but offered little sign of a durable resolution to longstanding trade differences that have affected products ranging from semiconductors and jet engines to medical equipment and pharmaceuticals. "What kind of long-term policy it could be, you know, what kind of tariff would it be in half a year, in one year... nobody knows. And that's the problem. That's what makes everybody worry and nervous," said Chen Gong, co-founder of NeuExcell Therapeutics, a biotech with its main operations in Suzhou. He said the U.S.-China trade tensions had made him more cautious about investing in a clinical trial and the company would delay its start if it did not have sufficient funding. Reliance on U.S. imports has come into particular focus as trade tensions escalate. In 2024, the U.S. exported diagnostic and laboratory reagents to China valued at about $1.4 billion and prepared culture media for the development or maintenance of microorganisms worth about $125 million, U.N. Comtrade data showed. In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare industry, some U.S.-made goods including diagnostic reagents from Germany's Siemens Healthineers were exempted from raised Chinese tariffs, that company said in May. China raised its tariffs on U.S. imports to as much as 125% though it has since reduced that to 10% while it works out a more permanent trade deal. HIGHER COSTS, DELAYS WuXi AppTec and a Chinese biotechnology firm that was its research client agreed in May to switch U.S.-made reagents they had been using for a Hepatitis B virus pre-clinical research project into non-U.S. versions due partly to concerns about higher costs from tariffs, a source at the client company said. The project had been temporarily paused during the discussions, which began prior to May, the source said. WuXi AppTec said it makes "every effort to avoid disruptions or delays in the delivery of services to customers." Since April, at least 17 Chinese biotech and pharmaceutical clients have contacted Chinese cell culture media manufacturer JS Biosciences asking it to keep locally-made backup raw materials for production because they were concerned about cost increases or the inability to access foreign supplies, the firm's CEO Luo Shun said. "If they have a product made by us, and we rely on the foreign raw material supply and that raw material will increase in price or is never going to come, obviously it will impact their manufacturing of those life-saving drugs. So obviously, that's their primary concern," Luo said. Another Chinese drug research and development firm decided not to provide a quotation to a foreign pharmaceutical company interested in hiring it for protein drug manufacturing, due to delays in obtaining necessary U.S.-made culture medium from a U.S. subsidiary of Japan's Fujifilm, a source at the Chinese firm said. The potential client would likely not have accepted waiting on imports of new supplies into China, which would typically take two to four months, the source said. A Fujifilm Holdings America Corporation spokesperson said Fujifilm Biosciences, one of its life science business units, has made significant investments to build a robust global manufacturing network so that it could navigate any challenges or disruptions, without elaborating on its supply issue involving China. STOCKPILING, US TESTING After China announced a large rise in tariffs for U.S. imports in April, WuXi Biologics placed a bigger-than-normal order for reagents made in the U.S. with a supplier because it was not sure how long that policy action would continue, said a source at the supplier. WuXi Biologics did not respond to requests for comment. Concerns about the potential for U.S. export restrictions led China's Innovent Biologics and multinational BeOne Medicines to discuss with Massachusetts-headquartered Thermo Fisher Scientific the prospect of not sending U.S. clinical samples to China, said a source at the U.S. company. Testing U.S. samples in-country instead of in China would be more expensive, the source said. A spokesperson for BeOne said it does not comment on rumours or speculation. Thermo Fisher and Innovent declined to comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
